Trial Profile

A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avutometinib (Primary) ; Everolimus
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Gynaecological cancer; Lung cancer; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions; Proof of concept
Acronyms RAF/MEK

18 May 2025 Planned End Date changed from 1 May 2024 to 1 Jun 2025.
18 May 2025 Planned primary completion date changed from 1 May 2024 to 1 Jun 2025.
18 May 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com